# Session 6: Donor perspectives on Xpert MTB/Rif 4<sup>th</sup> GLI Partners Meeting Annecy 19 April 2012

Michael Kimerling Global Health Program Seattle



#### Role of Diagnostics in TB program strategy

**TB** program Goal

Diagnostic role

Accelerate decline in TB <u>incidence</u>, focusing on interventions that reduce transmission...



...by increasing effectiveness of vaccines

Limited – currently no priorities identified




...by increasing early diagnosis and appropriate treatment of infectious cases


Reduce delay between onset of active disease and appropriate treatment via:

- Rapid/same day diagnosis upon first seeking care (first visit)
- Active case finding (targeted) in the community before suspect seeks care
- Rapid and accurate detection of suspects at point of care (community)
- Link new drugs/regimens to DST

## GeneXpert price reduction and Fast Followers are steps in long-term path to point of care TB Dx



## Need for impact evaluation; which diagnostic and when



Cobelens, et al. JID 2012

### **Dashboard of TB Diagnostic Investments**

Dx	Investment	Likely Impact <sup>1</sup>	Likely Technical Success
GeneXpert delivery and impact evaluation <sup>2</sup>	Multiple \$23 - \$26M		
Molecular Dx fast follower	TBD		
Biomarker for active TB and POC/Dx platforms	Multiple \$23M		

Key

<sup>&</sup>lt;sup>1</sup> Impact goal of TB team strategy

<sup>&</sup>lt;sup>2</sup> Excludes \$10M in development funding

## Long-term vision – POC Dx using new TB biomarker

#### TB biomarker discovery

- 12 grantees
- Well-characterized clinical samples from FIND
- Targeting based on
  - Diversity across broad set of markers and sample types
  - Risk balance

Initial results expected Q1 2014 to allow a down selection of promising candidates for further development

